Literature DB >> 22190193

[Cardiac rehabilitation: current status and future challenges].

H W Hahmann1.   

Abstract

The goal of cardiac rehabilitation is to support heart patients using a multidisciplinary team in order to obtain the best possible physical and mental health and achieve long-term social reintegration. In addition to improving physical fitness, cardiac rehabilitation restores self-confidence, thus better equipping patients to deal with mental illness and improving their social reintegration ("participation"). Once the causes of disease have been identified and treated as effectively as possible, drug and lifestyle changes form the focus of cardiac rehabilitation measures. In particular diseases, rehabilitation offers the opportunity for targeted educational courses for diabetics or drug dose escalation, as well as special training for heart failure patients. A nationwide network of outpatient heart groups is available for targeted follow-up. Cardiac patients predominantly rehabilitated in follow-up rehabilitation are older and have greater morbidity than in the past; moreover, they generally come out of acute clinical care earlier and are discharged from hospital more quickly. The proportion of severely ill and multimorbid patients presents a diagnostic and therapeutic challenge in cardiac rehabilitation, although cardiac rehabilitation was not initially conceived for this patient group. The benefit of cardiac rehabilitation has been a well documented reduction in morbidity and mortality. However, hurdles remain, partly due to the patients themselves, partly due to the health insurers. Some insurance providers still refuse rehabilitation for non-ST-segment elevation infarction. In principle rehabilitation can be carried out in an inpatient or an outpatient setting. Specific allocation criteria have not yet been established, but the structure and process quality of outpatient rehabilitation should correspond to that of the inpatient setting. The choice between the two settings should be based on pragmatic criteria. Both settings should be possible for an individual patient. Cardiac rehabilitation is already focusing on older, sicker and polymorbid patients; this will become ever more the case in the future. There is still a need for future clinical research for these patients.

Entities:  

Mesh:

Year:  2012        PMID: 22190193     DOI: 10.1007/s00059-011-3559-8

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  9 in total

Review 1.  Cardiac rehabilitation and secondary prevention of coronary heart disease.

Authors:  P A Ades
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

2.  [Guidelines for diagnosis and treatment of chronic coronary heart disease. Issued by the executive committee of the German Society of Cardiology--Heart Circulation Research in cooperation with the German Society for Prevention and Rehabilitation of Cardiac Diseases and the German Society for Thoracic and Cardiovascular Surgery].

Authors:  R Dietz; B Rauch
Journal:  Z Kardiol       Date:  2003-06

Review 3.  Current status of cardiac rehabilitation.

Authors:  Nanette K Wenger
Journal:  J Am Coll Cardiol       Date:  2008-04-29       Impact factor: 24.094

4.  Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.

Authors:  Jean-Pierre Bassand; Christian W Hamm; Diego Ardissino; Eric Boersma; Andrzej Budaj; Francisco Fernández-Avilés; Keith A A Fox; David Hasdai; E Magnus Ohman; Lars Wallentin; William Wijns
Journal:  Eur Heart J       Date:  2007-06-14       Impact factor: 29.983

5.  Effect of early short-term cardiac rehabilitation after acute ST-elevation and non-ST-elevation myocardial infarction on 1-year mortality.

Authors:  Claus Jünger; Bernhard Rauch; Steffen Schneider; Nadine Liebhart; Geraldine Rauch; Jochen Senges; Kurt Bestehorn
Journal:  Curr Med Res Opin       Date:  2010-04       Impact factor: 2.580

6.  [Secondary prevention in coronary patients after inpation rehabilitation].

Authors:  H Völler; G Klein; H Gohlke; C Dovifat; S Binting; J Müller-Nordhorn; S N Willich
Journal:  Dtsch Med Wochenschr       Date:  2000-12-01       Impact factor: 0.628

7.  Rehabilitation after cardiovascular diseases, with special emphasis on developing countries. Report of a WHO Expert Committee.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1993

8.  In-patient cardiac rehabilitation versus medical care - a prospective multicentre controlled 12 months follow-up in patients with coronary heart disease.

Authors:  Bernhard Schwaab; Annika Waldmann; Alexander Katalinic; Abdolhamid Sheikhzadeh; Heiner Raspe
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2011-01-31

9.  OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction.

Authors:  Bernhard Rauch; Rudolf Schiele; Steffen Schneider; Frank Diller; Norbert Victor; Helmut Gohlke; Martin Gottwik; Gerhard Steinbeck; Ulrike Del Castillo; Rudolf Sack; Heinrich Worth; Hugo Katus; Wilhelm Spitzer; Georg Sabin; Jochen Senges
Journal:  Circulation       Date:  2010-11-08       Impact factor: 29.690

  9 in total
  3 in total

1.  Guiding the failing heart to exercise.

Authors:  S Gielen; D Merkus; D J Duncker
Journal:  Neth Heart J       Date:  2015-01       Impact factor: 2.380

2.  Identifying Reasons for Nonattendance and Noncompletion of Cardiac Rehabilitation: INSIGHTS FROM GERMANY AND THE NETHERLANDS.

Authors:  Thijs Vonk; Malou A H Nuijten; Martijn F H Maessen; Esther P Meindersma; Hetty J J Koornstra-Wortel; Marc M Waskowsky; Johan A Snoek; Thijs M H Eijsvogels; Maria T E Hopman
Journal:  J Cardiopulm Rehabil Prev       Date:  2021-05-01       Impact factor: 3.646

3.  Designing a theory- and evidence-based tailored eHealth rehabilitation aftercare program in Germany and the Netherlands: study protocol.

Authors:  Dominique Reinwand; Tim Kuhlmann; Julian Wienert; Hein de Vries; Sonia Lippke
Journal:  BMC Public Health       Date:  2013-11-19       Impact factor: 3.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.